BK2069 Biotechnology
- 4442.693
- +22.563+0.51%
Perspective Therapeutics Q1 2024 GAAP EPS $(0.02) Beats $(0.03) Estimate, Sales $325.000K Up From $233.000K YoY
Perspective Therapeutics Q1 2024 GAAP EPS $(0.02) Beats $(0.03) Estimate, Sales $325.000K Up From $233.000K YoY
ScPharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 291.3% HC Wainwright & Co. → $18 Reiterates Buy → Buy 03/14/2024 291.3% HC Wainwright & Co. → $
Innate Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 359.08% HC Wainwright & Co. → $11.5 Reiterates Buy → Buy 04/11/2024 359.08% HC Wainwright & Co.
HC Wainwright & Co. Reiterates Buy on Absci, Maintains $7 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $7 price target.
Stifel Maintains Buy on Arcellx, Raises Price Target to $83
Stifel analyst Benjamin Burnett maintains Arcellx (NASDAQ:ACLX) with a Buy and raises the price target from $82 to $83.
Arcellx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 63.97% Stifel $82 → $83 Maintains Buy 05/14/2024 67.92% Evercore ISI Group → $85 Initiates Cove
Absci Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 45.83% HC Wainwright & Co. → $7 Reiterates Buy → Buy 03/26/2024 87.5% Truist Securities $9 → $9
Ocugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 316.67% HC Wainwright & Co. → $7 Reiterates Buy → Buy 04/22/2024 197.62% Chardan Capital $4 → $
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $6 price target.
Precigen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 337.96% HC Wainwright & Co. → $6 Reiterates Buy → Buy 03/22/2024 — JP Morgan Downgrades Neutra
Enliven Therapeutics GAAP EPS of -$0.54 Beats by $0.02
Tenaya Therapeutics GAAP EPS of -$0.40 Beats by $0.02
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 20 points on Wednesday.Shares of DLocal Limited (NASDAQ:DLO) fell sharply in today's pre-market trading after
Dare Bioscience Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 837.5% Brookline Capital → $3 Upgrades Hold → Buy 05/01/2024 1775% HC Wainwright & Co. → $6 Rei
Enveric Biosciences Q1 2024 GAAP EPS $(0.61) Beats $(0.78) Estimate
Enveric Biosciences (NASDAQ:ENVB) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.78) by 21.79 percent.
MEME stocks are back strongly! GME surged nearly 180% in two days. Who will be next?
The agency believes that more retail traders will join this trend in the next few days, but the possibility of reaching the level of 2021 is still relatively low.
Bio-Path Holdings Q1 2024 GAAP EPS $(4.88) Misses $(4.54) Estimate
Bio-Path Holdings Q1 2024 GAAP EPS $(4.88) Misses $(4.54) Estimate
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $7 price target.
Taysha Gene Therapies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 172.37% Needham → $7 Reiterates Buy → Buy 05/14/2024 211.28% Jefferies $2 → $8 Assumes Hold → B
Verona Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 128.41% HC Wainwright & Co. → $32 Reiterates Buy → Buy 05/13/2024 114.13% HC Wainwright & Co. $